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1 ABBREVIATIONS 
 
8-IP  8-Isoprostane 
8-OHdG  8-OH-deoxyguanosine 
AC   Adenocarcinoma 
BE  Barrett’s esophagus 
CHT  Chemotherapy 
CRT  Chemoradiotherapy  
CT  Computed tomography 
DFS   Disease free survival 
EGJ  Esophagogastric junction 
EMR  Endoscopic mucosal resection  
EOX  Epirubicin – Oxaliplatin – Cabecitabin 
ESD  Endoscopic mucosal resection 
EUS  Endoscopic ultrasound  
FDG  18F-fluorodeoxy-D-glucose 
FDG-PET  18F-fluorodeoxy-D-glucose positron emission tomography 
FDG-PET-CT  18F-fluorodeoxy-D-glucose positron emission tomography with  
  computed tomography 
GERD  Gastro-esophageal reflux disease 
GSH  Glutathione content, reduced form 
GSSG  Glutathione content, oxidized form 
HGD  High grade dysplasia 
HPI  Helicobacter pylorii infection 
HPR  Histopathologic response 
HR  Hazard ratio 
ICU  Intensive care unit 
LES  Lower esophageal sphincter 
LNM  Lymph node metastases 
MIE  Minimally invasive Ivor Lewis esophagectomy 
OE  Open transthoracic, Ivor Lewis esophagectomy 
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OEGD  Upper gastrointestinal endoscopy  
OR  Odds ratio 
OS  Oxidative stress 
PEG  Percutaneous endoscopic gastrostomy 
PET  Positron emission tomography 
RFA  Radiofrequency ablation 
ROC  Receiver operator characteristics 
ROI  Region of interest 
ROS  Reactive oxygen species 
SEAC  Superficial esophageal adenocarcinoma 
SM  Submucosal 
STS  Society of thoracic surgeons 
SUV  Standardized uptake values  
TH  Transhiatal esophagectomy 
TTE  Transthoracic esophagectomy 
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3 ABSTRACT 
 
Adenocarcinoma (AC) of the esophagus and esophagogastric junction (EGJ) is a disease with poor 
prognosis and increasing incidence in western countries. Its pathogenesis is associated with 
oxidative stress (OS) in the esophageal epithelium. Long-term survival is associated with successful 
radical surgery, early stage of the disease, and successful downstaging with neoadjuvant therapy. 
As surgery is accompanied with a large number of possible complications, it is essential to identify 
patients who might not benefit from surgery and on the other hand, could be treated with less 
invasive options. The aims of this study were 1) to assess the role of OS below EGJ in the 
pathogenesis of Barrett’s esophagus (BE) and AC, 2) to assess the prognoses and causes of death in 
early esophageal AC, 3) to determine the value of 18F-fluorodeoxy-D-glucose positron emission 
tomography with computed tomography (FDG-PET-CT) in quantifying the response to neoadjuvant 
therapy and 4) to compare the novel mini-invasive technique (MIE) to traditional open 
esophagectomy (OE) in radical surgery. 
To quantify OS, we measured 8-isoprostane (8-IP), glutathione content (GSH), and 8-OH-
deoxyglucose (8-OHdG) values from mucosa below EGJ, BE-mucosa, and AC-tumors from 43 
patients with BE and/or AC and compared them to samples from corresponding sites of 15 healthy 
control patients. To determine the long-term prognosis of patients with early esophageal AC, we 
studied patient records and causes of deaths for 85 patients, treated with radical esophagectomy 
over a 27-year time span. To evaluate pre-treatment response to neoadjuvant therapy in locally 
advanced AC, we recorded FDG-PET-CT results before and after induction therapy in sixty-six 
consecutive patients who were to be operated on for locally advanced AC. Decrement in radioactive 
glucose uptake values was associated with survival and histological treatment response. We 
compared MIE to OE, to see, if minimal invasiveness reduces the rate of complications and if they 
are comparable in terms of oncologic radicality and survival. 
Proximal gastric GSH content was lower and 8-IP and 8-OHdG levels higher with statistical 
significance in the study patients (BE and AC) as compared to healthy controls. In patients with early 
esophageal AC, overall and long-term (>5–year) survival rates were mostly affected by diseases 
related to aging. During the first five years after the operations, disease recurrence was the most 
common cause of death. However, recurrence-free survival was 80% at five years and no new 
recurrences were detected after that. Microscopic eradication of locally advanced AC was optimally 
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predicted by a 67% decrease in uptake values before and after induction chemotherapy, with a 
sensitivity of 79% and specificity of 75%. However, this association was not linear and complete 
eradication of radioactive glucose uptake, was not always associated with a complete histologic 
response. However, a decrease in glucose uptake was associated with improved overall and 
recurrence free survival. MIE and OE were equivalent in terms of 90-day mortality, pneumonia-, 
leak-, and overall complication rates. Also a minimally invasive technique was associated with 
significantly shorter overall hospital stay and significantly less blood loss during the operations. 
OS levels are also elevated below the EGJ, as lipid peroxidation can be detected (8-IP) and 
antioxidant defense (GSH) is reduced. Also the levels of 8-OHdG adducts were higher showing that 
DNA is being damaged by free radicals. This suggests that inflammation of the proximal gastric 
mucosa induced by gastroduodenal content, has a role in the pathogenesis of BE and esophageal 
AC. As the prognoses for patients with early esophageal AC were good, recurrence was still the most 
important cause of death. The risk was highest for patients with lymph node metastases and deep 
submucosal infiltration. Therefore radical surgery should be preferred with patients with a low risk 
of surgical complications and submucosal infiltration. In patients with intramucosal AC, endoscopic 
ablation should be considered. Evaluation of the patients’ responses to induction chemotherapy 
with FDG-PET-CT was not accurate enough to give indications better than the exclusion of 
metastatic disease. However, a significant decrease in radioactive glucose uptake was associated 
with improved survival, independently of histopathologic response. This information can be useful 
when balancing the risks of surgery against expected benefits. The perioperative and oncological 
results for MIE were comparable to those of the open approach and MIE seems to shorten hospital 
stay. However, the MIE technique is demanding and its mastery requires a sufficient number of 
cases and skilled practitioners. 
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4 INTRODUCTION 
 
Esophageal carcinoma consisting of adenocarcinomas (AC) and squamous cell carcinomas is the 8th 
most common cancer worldwide and 6th most common cause of cancer related death (1). The 
incidence of AC has been rising rapidly in high-income western countries, replacing squamous cell 
carcinoma as the most common histological subtype (2-7). AC of the esophagus and EGJ, is a disease 
with poor prognosis, as at the time of diagnosis, 60% of patients can only receive palliative 
treatment because of underlying illnesses and / or disseminated disease. The expected overall 5-
year survival of all patients is 17% (8, 9). It is possible to cure the disease if it is diagnosed at an early 
stage and if the patients are treated with radical esophagectomy, with experienced centers 
achieving 40-50% overall 5-year survival rates (1, 8, 9). 
The incidence of AC has undergone a dramatic increase over the last 40 years. In the United States, 
from 1975 to 2004, the age-adjusted incidence of esophageal carcinoma in white men has increased 
463%, from 5.76 to 8.34/100000/year (10). In Finland a similar increase has been seen with the 
incidence in males jumping from 0.28 to 0.77/100000/year between 1976 and 1995 (8) and from 
1995-2012 0.8–2.1/100000/year (Figure 3). Obesity, gastro-esophageal reflux disease (GERD) and 
tobacco smoking are the principal factors associated with an increased risk for AC of the esophagus 
and EGJ (11, 12) and the rise of its incidence can be attributed to changes in prevalence of those 
factors (12). At highest risk of esophageal AC, are patients with GERD, who have acquired Barrett’s 
esophagus (BE) and approximately 60% of patients with AC have this condition (13-16). It is 
estimated, that 10% of patients with BE, have a genetic predisposition (17) for the condition. The 
annual risk of esophageal AC in patients with BE is 0.12% and the risk is increased to 5% when 
metaplasia progresses to low grade dysplasia (18). The role of Helicobacter pylori infection (HPI), 
the most important risk factor for gastric AC, is unclear in the development of EGJ AC. As some 
studies have connected HPI with EGJ AC, recent meta-analysis suggests it grants a protective effect 
against AC in general (19).  
Chronic inflammation in the esophageal mucosa caused by GERD, is considered to be the main 
mechanism behind the development of BE and subsequent dysplasia and AC in the esophagus (14, 
20, 21). Chronic inflammation leads to a state of oxidative stress (OS) i.e. accumulation of toxic 
oxygen free radicals that damage cell membranes, proteins and DNA making a patient susceptible 
to mutations that may lead to carcinogenesis (22, 23). OS has been shown to strongly associate with 
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the development AC of the esophagus and EGJ (23-26). On the other hand, an increased intake of 
antioxidants has been associated with a lesser risk of AC (27). Patients with GERD and without 
esophagitis seem to have increased OS and deficient antioxidant barrier in their proximal 
esophageal mucosa, and this remains unchanged even after successful fundoplication (24). In the 
gastric cardia, inflammation has been associated with HPI, but also with GERD (28) and inflammation 
of the cardia has been linked with AC of the EGJ (29). The importance of OS in the proximal gastric 
folds of patients with GERD, BE and AC is largely unknown. 
In the last decades, the overall mortality to AC of the esophagus and EGJ has not decreased, but 
incidence based mortality due to the early stage disease has decreased, which may be largely 
attributes to BE surveillance programs and treatment at an early stage (30). Radical surgery offers 
the possibility of curing patients with AC, but it is associated with substantial rates of complications 
(31) and mortalities (32). International guidelines suggest endoscopic mucosal resection (EMR) or 
endoscopic submucosal dissection (ESD) with radiofrequency ablation (RFA) of residual BE 
segments, for patients with high grade dysplasia and intramucosal esophageal cancer (pT1a), as it 
is reported that the incidence of lymph node metastases (LNM) and recurrence are very low (33, 
34) and the morbidities associated with radical surgery can thus be avoided. However, as patients 
with early esophageal AC are mostly older and may not live over the 5-year follow up period, it is 
not known for how long the risk of disease recurrence persists and what are causes of death in this 
patient population. This data is necessary to inform optimal selection for therapy.  
Neoadjuvant therapy with chemo- or radiochemotherapy has improved results of locally advanced 
AC (35, 36). Nearly 20-25% of patients may have a complete histopathologic response, which is 
associated with markedly improved survival (37). As neoadjuvant therapy may also cause 
complications and delay of surgery, there would be a need to find an imaging modality to select 
patients who can or cannot benefit from the multimodality approach, or even from resection. 
Positron emission tomography (PET) measures the accumulation of a fluorinated glucose analog 
(18F-fluorodeoxy-D-glucose; FDG) in malignant cells (38). It is more accurate in detecting distant 
metastases than computed tomography (CT) (39, 40). The accumulation of FDG offers a possibility 
to grade the activities of tumors during and after treatment with repeated scans and it has been 
shown to be able to grade treatment response during neoadjuvant chemotherapy (41).  
As esophageal resections are associated with a high rate of complications, traditional en-bloc open 
transthoracic esophagectomy (OE) has been replaced in many experienced centers with the 
videothoracoscopic and laparoscopic approaches i.e. minimally invasive esophagectomy (MIE) (42-
13 
45). Randomized data from a single institution suggests these approaches lead to less pulmonary 
complications, shorter hospital stays and improved short-term quality of life for MIE (46). There is a 
lack of data concerning oncologic safety for patients with locally advanced AC who are operated on 
after neoadjuvant therapy. 
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5 REVIEW OF THE LITERATURE 
 
5.1. Definition of histology and anatomy 
AC of the esophagus and EGJ, occurs in the distal third of the esophagus or in the EGJ (47) and it is 
classified according to the International Union Against Cancer and the American Joint Committee 
for Cancer (UICC/AJCC) TNM staging system (48). AC is rarely located more proximally than the 
tracheal bifurcation (9). It is not possible to define EGJ AC histologically, as columnar elements found 
in those tumors are also present in the normal mucosa of the proximal stomach, distal esophagus 
and Barrett’s metaplasia (49). The Western endoscopic definition of cardia is the top of the gastric 
folds, whereas the Japanese define it as the lower limit of the palisade vessels (50-52). The histologic 
definition of cardia is also unclear, as the squamocolumnar junction and EGJ may not coincide and 
cardiac type distal esophageal mucosa, or a mixture of fundic, cardiac and intestinalized mucosa 
may be present in this area (Figure 1) (53, 54). The modern concept is, that a mixture of columnar 
cell types is found between true squamous or intestinal metaplastic-, and true gastric mucosa, called 
the squamo-oxyntic gap. It is strongly associated with reflux, and cannot be seen in autopsy studies 
of patients without reflux (50, 55). To overcome these difficulties of definition for clinical purposes, 
a clinical topographic classification has been described by Siewert et al. (56) (Figure 1). Tumors 
reaching EGJ are divided into three classes. Class I tumors are those that have their epicenter within 
5 cm of the cardia in the distal esophagus, class II tumors have their epicenter within 1 cm above or 
2 cm below the EGJ, and class III subcardial tumors having their centers of mass 2-5 cm from the 
EGJ. Type I tumors are thought to arise from the esophageal mucosa, type III tumors from the fundic 
gland mucosa and type II tumors from both.  
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Figure 1. Siewert’s classification of tumors near the esophagogastric junction and the transition of 
mucosa from squamous esophageal epithelium to true gastric mucosa. 
 
5.2 Barrett’s esophagus 
5.2.1 Definition  
Metaplasia is defined as a process where one adult cell type replaces another as a consequence of 
chronic tissue injury (57). Barrett’s esophagus (BE) is nowadays defined as a condition in which 
metaplastic columnar mucosa that has a risk of becoming cancerous, replaces esophageal squamous 
mucosa that has been damaged by gastroesophageal reflux disease GERD (14). Its diagnosis requires 
biopsy confirmed esophageal intestinal metaplasia with specialized goblet cells in any distance from 
proximal gastric folds, although some gastroenterologic societies also only accept cardiac columnar 
mucosa for the diagnosis (14, 58). The prevalence of BE is 5.6% and 4% in the American (14) and 
Finnish populations (59) respectively. 
 
5.2.2 Pathogenesis 
GERD is generally accepted as the cause of BE (14, 60-62). The most important cause for GERD is 
lower esophageal sphincter (LES) insufficiency, causing more than half of reflux episodes in reflux 
patients (63-65) Other important ailments affecting reflux and esophageal injury are hiatal hernia, 
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impaired esophageal emptying, and delayed gastric emptying (66, 67). It has been reported that 
90% of patients with BE have mechanically insufficient LES and 93% have increased exposure to 
gastric contents according to pH monitoring (63). Refluxing contents that damage the esophageal 
mucosa are acid, pepsin and duodenal contents, such as trypsin, bile acids and bile salts (68-73). In 
BE, the squamous epithelium is replaced by mucus secreting columnar cells that have better 
tolerance to acid and bile (73). The metaplastic process can be the result of a direct conversion from 
differentiated squamous epithelial cells to metaplastic mucosa or a change in the development of 
the esophageal or intestinal stem cells to BE mucosa (57, 74). It is unclear what cells give rise to 
metaplasia, but esophageal stem cells, stem cells of the submucosal glands, and stem cells of the 
gastric cardia have been suggested (75) as candidates. In a rat model, BE develops from circulating 
stem cells originated in bone marrow (76). A genetic predisposition to the development of BE is 
known to exist and 10-12% of all patients with BE are considered to have a familial background (17, 
77). Therefore, the concept of BE being an acquired condition, is being challenged (77). 
 
5.3 Oxidative stress 
An organism’s oxidative metabolism produces reactive oxygen species (ROS) as byproducts, which 
are generated when oxygen molecules are reduced. A one-electron reduction of oxygen produces 
superoxide, whereas a two-electron reduction produces hydrogen peroxide (78). ROS are a part of 
normal oxygen metabolism but when in excess, they are a threat as they can cause oxidative injury 
to cells by damaging DNA, proteins and cell membranes (79). Free radicals can modify DNA bases 
and cause the production of DNA adducts, such as 8-OHdG, and these mutations can lead to further 
mutations that cause the dysfunction of key genes and the initiation of carcinogenesis (79, 80). OS 
has been suggested to play a key role in GERD related chronic injury esophageal mucosa (81). The 
expression of inflammatory cytokines in response to damage induced by gastroduodenal reflux, 
leads to infiltration of inflammatory cells to the esophageal mucosa, and their activity results in the 
overproduction of ROS (81). Studies of BE and esophageal AC in human tissues (24, 25, 82, 83) and 
animal models (84) have shown that there are increased OS markers and decreased antioxidative 
capacity as compared to normal squamous epithelium and duodenal mucosa. Also, consequent DNA 
damage has been demonstrated in BE and esophageal AC tissues as compared to normal squamous 
mucosa of the esophagus (80, 83, 85, 86). In other GI-tract malignancies, for example esophageal 
squamous cell carcinoma (87), and gastric AC, OS plays an essential role. The pathogenesis of peptic 
ulcer disease and gastric AC are driven by Helicobacter pylori infection associated oxidative stress 
17 
(88, 89). Cellular antioxidant mechanisms are essential for protecting esophageal epithelial cells 
against the ROS generated by GERD. Glutathione S-transferase (GST), glutathione peroxidase (GPx) 
and superoxide dismutase (SOD) systems play crucial roles in cellular detoxification, protecting 
macromolecules from attack by reactive electrophiles. Reduced levels of these enzymes, and/or 
reduced glutathione have been reported in BE and Esophageal ACs, implying that an impaired 
antioxidative defense may contribute to the carcinogenesis of esophageal AC. (25, 26, 90, 91). 
Increased antioxidant dietary intake is associated with reduced risk of esophageal AC, which further 
supports the role of oxidative damage (92, 93). Overall, mutations in genes controlling cellular 
antioxidant defenses represent a key step in the development of BE and subsequent carcinogenesis 
(75). 
 
5.4 Epidemiology 
The incidence of AC has been rapidly rising in western countries during the last four decades (Figure 
2 and 3) and it has replaced squamous cell carcinoma as the most common histological subtype (2-
4, 94). This change has coincided with an increase in obesity and GERD, and on the other hand, a 
reduction in smoking and alcohol consumption (7, 11, 16). Incidence rates have been highest in 
Great Britain (5-8.7/100000/year), Australia (4.8/100000/year), the Netherlands (4.4/100000/year) 
and the USA 3.7/100000/year (2). In Finland, the incidence of esophageal AC in males rose from 
0.28 to 0.77/100000 between 1976-1995 (95), during the years 1998-2002 it rose to 1.10/100000 
(96) and according to the Finnish cancer register, from 1.2 to 2.1/100000 during 2001-12 (Figure 3). 
Other Nordic countries have had a similarly low incidence, Denmark (2.8/100000/year), Sweden 
1.0/100000/year and Norway 0.8/100000/year (2). 
Recent reports from the USA (97) suggest that the incidence of esophageal AC is plateauing from an 
8.2% annual rate of increase to 1.3% and a Swedish study (6) reports that the incidence in Sweden 
has remained stable since 2001. Another recent report shows that the incidence in the USA has 
been growing steadily annually at a rate of 2.2% and it grew in Australia by 1.5% between 1998 and 
2008 (98). So the overall incidence still appears be growing, but at a slower pace. The rise in 
incidence of AC of the EGJ has plateaued earlier than that of AC of the esophagus, having remained 
at 2/100000/year since 2000 in the US (99). Overall, the worldwide variation in incidence of 
esophageal AC is much less than that of squamous cell carcinoma. Differences occur in genders and 
races in the same geographical areas, for example, in the USA esophageal AC is five times more 
common in whites than blacks, and eight times more common in men than women (100). In Finland 
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the incidence of AC between 1991 and 1995 was 7-fold higher in men than women (0.77 vs. 
0.11/100000/year) (95) as seen in a study by Voutilainen et al. (96). Values in other European 
countries are: a male to female ratio of 12:1 in France, 2:1 in the Netherlands, 5.5:1 in Denmark and 
9.6:1 in Iceland (101). If AC of the EGJ is examined separately, its incidence can be seen to have 
plateaued earlier than of AC of the esophagus, having remained at 2/100000/year since 2000 in the 
US, and at the same time, the incidence of true gastric AC has decreased steeply (99). EGJ AC has a 
similar male to female ratio (4.7:1 in the USA) and black to white ratio (2:1 in the USA) (99). 
Misclassification of esophageal AC as true gastric AC may have occurred and the effect of such 
misclassification on the incidence is unknown (2, 99, 102). In Finland, the incidence of EGJ AC has 
remained the same over the last decades (2.1/100000/year in males and 0.5/100000/year in 
females) (95, 96). Finnish cancer registry data suggests that during 1995- 2012, the incidence of 
cardiac adenocarcinomas in both men and women has remained stable, between 0.8-
1.4/100000/year. 
 
 
Figure 2. Age-adjusted incidence rates (blue bars) and 5-year survival rates for persons with 
esophageal adenocarcinoma diagnosed in the United States. Data are from the population based 
Surveillance, Epidemiology and End Results cancer registries. Reproduced with permission from 
Rustgi et al., NEJM 2014 (9), copyright Massachusetts Medical Society. 
.  
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Figure 3. Age-adjusted incidence rates for persons with esophageal adenocarcinoma diagnosed in 
Finland between 1995 and 2012. Data acquired from the Finnish cancer register. 
 
5.5 Risk factors 
In most cases esophageal AC originates from a region of the BE in a stepwise process from GERD 
associated chronic inflammation to metaplasia, dysplasia, and finally AC (13, 14, 20, 21, 103). The 
annual risk of developing esophageal AC for patients with BE, is 30-fold compared to the general 
population and the absolute risk is 0.12% per year (18). GERD is known to be a risk factor even in 
the absence of BE (15) and the severity of symptom scores has been associated with increased risk 
of AC (104). Factors increasing the risk of BE progression are hiatal hernia, length of BE segment >3 
cm, dysplastic lesions and ulceration (105-107). Other significant risk factors are obesity and 
smoking. Meta-analyzes showed a pooled 2.78 (95%CI 1.850-4.164) fold risk for AC in patients with 
BMI over 30kg/m2 (108) and 1.96 (95%CI 1.64-2.34) fold risk for smokers (109). Previous 
cholecystectomy raises the risk to 1.3 (95%CI 1-1.8) (110). In a recent meta-analysis high fiber 
nutrition was associated with significantly decreased risk of esophageal AC (OR 0.66; 95%CI 0.44-
0.98) (111) but alcohol consumption did not affect the risk (112). 
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AC of the esophagus and EGJ share the same risk factors, but the risks are lower for EGJ AC (99, 
103). There are also reports of EGJ AC arising without BE (113-115). It is thought that EGJ AC has a 
more heterogeneous origin than esophageal AC with the clinicopathologic features, however, being 
the same as in BE originated AC (49, 115). HPI may be associated with subcardiac (Siewert type III) 
AC but its presence is inversely associated with the risk of esophageal AC (19). It has been proposed 
that the prominent decline in HPI colonization in the last few decades may partly be responsible for 
the increase seen in the incidence of esophageal AC (116, 117). The association between EGJ AC and 
HPI is considered to be unclear (116-118). Other protective factors may be the use of anti-
inflammatory medication (119), statins (120) and antioxidants (27). 
 
5.6 Clinical presentation and diagnosis 
Most esophageal ACs (75%) are located in the distal third of the esophagus and AC of the EGJ is 
considered to be a continuation of the same process (9). Small tumors may be asymptomatic, while 
locally advanced tumors cause progressive dysphagia and weight loss. Other common symptoms 
are heartburn and blood loss (9). Barium swallow has a 95% sensitivity for detecting tumors and is 
considered a safe and inexpensive method, but upper gastrointestinal endoscopy (OEGD) is the 
method of choice to confirm the presence of even small tumors and for making possible biopsies 
with histological diagnosis (121, 122). 
 
5.7 Staging 
Once diagnosis of AC is made, the next goal is to evaluate if the patient is a candidate for complete 
surgical resection. Staging is accomplished in accordance with the latest version of the International 
Union against Cancer and American Joint Committee for Cancer (UICC/AJCC) TNM staging system 
(48) (Figure 4 & 4.1). The TNM stage involves the depth of infiltration of the tumor into the 
esophageal wall (T), the lymph node status (N) and the possible presence of distant metastases (M). 
The latest version is from 2010 and the most significant changes to the previous system are that all 
distant metastases are classified as M1 instead of M1a and M1b. A regional lymph node has also 
been redefined to be any periesophageal node from the cervical to the coeliac areas. Therefore, for 
example, retroperitoneal and supraclavicular metastatic nodes are considered as stage IV (M1) 
disease. Also, the N class is stratified according to the amount of regional lymph node metastases 
and T4 is divided into resectable (T4a) and unresectable T4b. 
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The workup for staging includes evaluation of the history and general physical condition of the 
patient, OEGD to determine the location and extent of the tumor, CT of the abdomen and chest, 
endoscopic ultrasound (EUS) and FDG-PET-CT (123). FDG-PET-CT is always used in assessing patients 
who are being considered for an operation. However, if CT of the abdomen and chest reveals distant 
metastases, FDG-PET-CT is not necessary. Minimally invasive staging (laparo-, thoraco- or 
mediastinoscopy) may also be used in unclear situations (124). 
 
5.7.1 T & N –staging 
EUS (Figure 5, panel B) can evaluate the esophageal wall in detail and the accuracy of determining 
tumor depth (T-stage) is between 73% and 89% and for lymph node status (N-stage) 69%-83% 
accuracy as compared to histopathological staging from surgical specimens (125, 126). Fine needle 
sampling with EUS can increase the accuracy of N-stage determination to 90% (127). In the early 
stages of AC (stage 0, Figures 4 and 4.1), i.e. high-grade dysplasia (HGD, stage 0) and intramucosal 
tumors (T1a, stage Ia), tumors do not invade through the lamina propria. Submucosal tumors (T1b, 
Stage Ib) invade the lamina propria layer, i.e. the submucosal layer of the esophageal wall (stage I, 
Figure 4). The accuracy of EUS in separating stage 0 and Ia from stage Ib, is however inferior to 
endoscopic mucosal resection (EMR), as only 54% of T1 tumors were staged correctly according to 
a meta-analysis (128). Therefore EMR is recommend for the more accurate staging of early stage 
tumors. Tumor stenosis may prohibit the use of EUS and all nodes cannot be reached with a needle. 
EUS is the most accurate method for determining local disease (stage Ib-IIa, Figures 4 and 4.1) from 
locally advanced (stages IIb-IIIc, Figures 4 and 4.1) (129, 130). If metastases or an extension to 
adjacent organs are not present, CT gives more reliable information of the tumor stage (129, 130). 
The accuracy of PET in the detection of N-status is more variable and its accuracy is between 27%-
90% and it is not useful in the evaluation of T-status (131). The use of PET-CT has improved the 
accuracy of detection of the regional lymph node metastases, but EUS still seems to be a more 
accurate predictor of nodal status (132). 
 
5.7.2 M-staging 
The first goal of staging is to exclude metastastic (stage IV Figures 4 and 4.1) disease, as those 
patients do not benefit from surgical therapy and further staging is not needed. CT of the abdomen 
and chest that can detect stage IV disease with an accuracy of 80% (133-136), is readily available 
and relatively inexpensive and therefore first-line modality. FDG-PET is superior to all other 
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modalities in the detection of stage IV disease (137-141). Combining PET and CT has further 
improved the staging accuracy of PET (142-144). Most metastases appear in solid organs, non-
regional lymph nodes and bone (131, 145). Distant nodal metastases remain a challenge to both CT 
and PET, as they lack accuracy when the nodes are less than 10 mm in diameter. PEt al.so has a risk 
for false positive findings as inflammatory lesions also have increased uptake of FDG (138, 141). 
However, overall the use of PET-CT results in the detection of more advanced disease in 10-20% of 
patients, as PET-CT may identify occult distant nodal metastasis especially in supraclavicular and 
retroperitoneal areas not detectable by CT (9). 
 
5.7.3 Treatment response evaluation 
Multimodality therapy i.e. neoadjuvant therapy in conjunction with surgery is increasingly used to 
improve the treatment results of locally advanced esophageal AC (146). Re-staging after 
neoadjuvant therapy is necessary to evaluate if a patient is going to benefit from continuing with 
neoadjuvant and if surgery is still feasible. CT, EUS and OEGD have been shown to be inaccurate in 
neoadjuvant response evaluation (141, 147, 148). However sequential metabolic imaging by PET 
and PET-CT has been shown to correlate with neoadjuvant chemotherapy response and survival 
after surgery, much better than CT or EUS (38, 41, 149, 150), but its accuracy is not high enough to 
predict histopathologic complete remission of the disease. The present results are contradictory 
when trying to predict responses to neoadjuvat chemoradiotherapy, mostly because of radiation-
induced inflammation (146, 147, 151-153). 
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Figure 4. Reproduced with permission from Rustgi et al., NEJM 2014 (9), copyright Massachusetts 
Medical Society.  
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Figure 4.1  
Esophageal adenocarcinoma stage groupings (48).  
 
5.8 Treatment 
The general consensus remains that surgical treatment of esophageal AC is the key for cure and 
restoration of swallowing function (154-156). In recent years two randomized studies (157, 158) 
have suggested that overall survival is not improved with the addition of surgery to definitive 
chemoradiation in esophageal epidermoid carcinoma, although palliation of dysphagia and disease 
free survival are better in surgery groups. Therefore chemoradiation is frequently offered as a 
definitive treatment to patients with high surgical risk and epidermoid histology. However, there is 
no such evidence for AC of the esophagus as prolonged survival with definitive chemoradiation has 
been reported in only selected patients with esophageal AC (159) and the results do not compare 
with the best surgical series. 
Treatment of esophageal AC is defined according to tumor stage and for the purposes of treatment 
it can be divided according to the latest classification (48) as early (stages 0-Ia), localized (stages Ib 
- IIa ), locally advanced (stages IIb - IIIc i.e. T3-4 and N0-3 or any T and N1-3) and patients with distant 
metastasis (stage IV). Patients with T1a and T1b esophageal AC may have 65-85% 5-year survival 
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after surgery (160-166) and similar survival rates have been reported after endoscopic mucosal 
resection (EMR) for early esophageal AC (167). In locally advanced esophageal AC, experienced units 
(39, 168-171) have reported up to 40-50% 5-year survival after neoajuvant therapy and surgery, but 
with surgery only, the results are disappointing with 5-35% 5-year survival (172). 
The first determinant of prognosis after surgical resection is the status of the resection margins, and 
the survival of patients with positive margins is poor, 0-14% at 5 years after operation (173, 174). In 
patients with completely resected disease, the prognosis is independently associated with the 
presence of regional lymph node metastases and also their number (173-177). Regional lymph node 
status is predicted by the depth of tumor infiltration (177, 178). After induction therapy, lymph node 
metastases and histopathologic regression of the tumor are both independent predictors of survival 
(179). Patients with complete histopathologic response have been reported achieving similar 5-year 
survival rates as stage I & II patients, and at best 67% disease-specific 5-year survival in retrospective 
series (37, 179, 180). 
 
5.8.1 Early stage tumors (stage 0-Ia) 
Early esophageal AC is defined as either high-grade dysplasia (HGD) or intramucosal AC (T1a) (48) 
(Figure 5, panel A). HGD has almost no risk for nodal metastasis, but resected specimen may harbor 
occult invasive cancer in up to 12% of patients (181). For intramucosal cancer, the risk of nodal 
disease is 0-2% (182). As the risk of nodal metastasis is very low, endoscopic treatment is generally 
recommended as a first line therapy for HGD and T1a tumors (33). Different methods include argon 
beam coagulation, photodynamic therapy, EMR, ESD, radiofrequency ablation (RFA), cryo- and laser 
therapy. Of these, most commonly EMR is used to remove visible lesions and residual metaplastic 
mucosa is ablated with RFA (Figure 5, panel C-F) (183). EMR allows for histopathologic diagnosis and 
the most accurate staging of the possible invasive AC and may lead to further esophagectomy if 
necessary. A German group compared the results of surgical and endoscopic treatment in 114 
patients with early AC (184). Surgery was associated with morbidity, and local recurrence were more 
likely in the EMR group and frequent follow-ups necessary (184). However, similar long-term results 
can be achieved with both endoscopic and surgical treatments (167). According to a recent meta-
analysis, the risk of recurrence after endoscopic therapy is associated with higher tumor grade, 
lymphovascular- and microvascular infiltration, piecemeal resection and metachronos in-situ 
carcinoma (185) and the presence of those risk factors are considered to support surgical treatment 
over endoscopic. The ESD method is increasingly utilized, as a larger piece of mucosa may resected 
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in one piece. A review of retrospective analysis suggests a lower rate of cancer recurrence but an 
increased risk of perforation and bleeding as compared to EMR (34). 
 
 
Figure 5. Reproduced with permission from Rustgi et al., NEJM 2014 (9), copyright Massachusetts 
Medical Society. 
 
5.8.2 Local tumors (stage Ib - IIa) 
Tumors extending to the submucosa (T1b) or infiltrating muscularis propria layer, are defined as 
locally infiltrating tumors (48). The submucosal layer can be divided into three layers classified as 
SM1 (superficial one-third), SM2 (middle one-third), and SM3 (deep one-third) according to a 
Japanese classification (186). The risk of nodal metastases increases steeply when the tumor 
infiltrates the submucosal layers, and is between 27-41% in T1b tumors (160, 173, 178, 187, 188) 
and in a large series after radical resection up to 50% risk of nodal metastasis is reported in tumors 
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clinically staged as T2 (173, 177, 178). Good results from endoscopic therapy of T1b tumors with 
infiltration limited in the superficial one-third (SM1) have been reported (189) but other studies 
have reported alarmingly high rates of nodal metastases also in the SM1-category (160, 190) and 
generally surgery is recommended for the T1b-T2 category of tumors (9, 154, 156). Clinical T2 
matches the pathological stages with modern methods in fewer than 17-27% of patients, and most 
likely the patients have higher stages (45-67%) than expected (191, 192). It is unclear, whether the 
survival benefit of induction therapy to cT2N0 patients outweighs the risk and costs associated with 
induction treatment and the practice is variable. According to the STS database, between 2002 and 
2011 35.9% of patients with clinical T2 received neoadjuvant therapy (192), which is more than 
earlier reports indicate (193). In a randomized study, neoadjuvant therapy in stage I-II esophageal 
cancer was associated with adverse events with little or no survival benefit (194) and at present it 
is generally not recommended. 
 
5.8.3 Locally advanced tumors (stage IIb - III) 
Tumors staged as T3-T4a or with detected regional lymph node involvement, constitute locally 
advanced esophageal AC (48). In a large series of radical resections, adenocarcinomas with pT3 level 
infiltration are 81-83% likely to have lymph node metastases and in pT4 category 93%-100% have 
nodal disease (173, 177, 178). Therefore R0 resection with radical, at least two-field lymph node 
dissection is generally considered the best treatment (154). However, as nearly 60% of patients tend 
to develop distal or local recurrence within 2 years after surgery alone (169, 172, 173, 178) we have 
to resort to oncologic induction therapy to improve resectability, recurrence rate and survival. 
Theoretically chemotherapy should eliminate circulating malignant cells and radiotherapy improves 
the local control rate. Chemo- (CHT) and chemoradiotherapy (CRT) have been utilized for this 
purpose and several meta-analyzes have been published with the most recent and important being 
from Gebski and Sjoquist (35, 36). Gebski et al. compared the results of 10 randomized trials of 
neoadjuvant CRT vs. surgery alone and 8 randomized trials of neoadjuvant chemotherapy vs. 
surgery alone in patients with locally resectable esophageal AC and epidermoid carcinoma. CHT 
gave the AC group significant survival benefits (HR for mortality 0.78 (0.64-0.95); p=0.014), whereas 
patients with epidermoid histology did not benefit. CRT was of benefit for both types of histology 
and the mortality HR was 0.75 (0.59-0.95; p=0.02) for adenocarcinoma. Sjoquist et al. updated the 
previously meta-analysis by including all 17 trials from the previous meta-analysis and seven further 
studies. The HR for all-cause mortality after neoadjuvant CHT in AC group was 0.83 (0.71-0.95; 
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p=0.01) and after CRT 0.75 (0.59-0.95; p=0.02). The HR for the overall indirect comparison of all-
cause mortality for neoadjuvant CRT versus neoadjuvant chemotherapy was 0.88 (0.76-1.01; 
p=0.07). The latest randomized trial compared the outcome of CRT followed by surgery and surgery 
alone (168). The median overall survival rate was 49.4 months for the CRT and surgery group 
compared to 24 months for the surgery only group. Overall survival was significantly better in the 
CRT group [HR 0.657 (0.495-0.871; p=0.003)]. Overall, the evidence strongly supports the use of 
neoadjuvant therapy in patients with locally advanced esophageal AC. Meta-analyzes suggest better 
response to CRT than CHT and CRT is utilized more widely. The variations in treatment protocols 
and practices are wide and therefore definite answers cannot be presently drawn for optimal 
neoadjuvant regimen. The role of postoperative adjuvant therapy in esophageal AC is unclear. A 
randomized trial by Cunningham et al. demonstrated a survival benefit of preoperative CHT and 
surgery as compared to surgery alone (195). Chemotherapy consisted of three preoperative and 
three postoperative cycles of intravenous epirubicin and cisplatin and a continuous intravenous 
infusion of fluorouracil for 21 days. There was a significant survival advantage to CHT + surgery 
group over the surgery only group. All the patients did not complete post-operative cycles of 
chemotherapy due to complications, side effects and disease progression and it was concluded it is 
impossible to evaluate the role of post-operative chemotherapy. However, many centers that 
administer neoadjuvant CHT, also continue postoperative cycles according to this protocol. In 
another trial, postoperative adjuvant therapy with paclitaxel and cisplatin improved 2-year survival 
as compared to historical controls suggesting there is some benefit (196). In a randomized trial by 
Macdonald et al., postoperative CRT improved survival significantly over a surgery only group in 
patients with AC of the stomach or ge-junction (197) and patients with gastric cancer are frequently 
offered postoperative CRT. Overall, postoperative therapy is problematic due to the poor condition 
of patients after resection, complications and the fact that not all patients are eligible for those 
treatments. 
 
5.8.4 Metastatic disease (stage IV) 
Treatment in stage IV disease is palliative as the expected survival despite treatment is less than 6 
months (198, 199). The addition of chemo- or radiotherapy may prolong survival and also quality of 
life for up to 9 months if a response is achieved (200, 201). Palliative oncologic therapy should 
therefore be offered to patients with good general condition.  
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In symptomatic malignant obstruction of the esophagus, endoscopic interventions may be used. An 
easy and effective option is the insertion of self-expanding metallic stents (SEMS) (202). Stents are 
the most used option because of their rapid and easy placement and rapid relief of obstruction and 
they seem to produce the best long-term relief of dysphagia as compared to other local therapies 
such as laser, photodynamic therapy or brachytherapy (203). SEMS are however associated with re-
occlusion due to food boluses, stent migration and tumor granulation tissue overgrowth is found in 
20-55% of cases, and the technique has 45% morbidity and 9% mortality rates (204). Stent occlusion 
can be managed in most cases by combining balloon dilatation, endoscopic removal of food boluses, 
re-stenting and laser therapy (205). In cases with hemorrhaging tumors, radiotherapy may provide 
a more lasting effect, if tumor bleeding cannot be controlled by laser treatment or stenting (206). 
In cases where the stent cannot be placed, i.e. because of a difficult location, or the stent does not 
produce palliation dysphagia due to complications or loss of appetite, a percutaneous endoscopic 
gastrostomy (PEG) or surgically placed jejunal feeding tube can allow a secure route for enteral 
nutrition (207). 
 
5.8.5 Operative techniques and complications 
The traditional technique to achieve radical esophagectomy is a transthoracic (Figure 6) (208, 209) 
approach with upper midline laparotomy, right thoracotomy, and intrathoracal anastomosis (Ivor 
Lewis esophagectomy). Another common transthoracic operation is the McKeown approach, 
consisting of laparotomy, right thoracotomy and cervicotomy for neck anastomosis (210, 211). Also, 
the left thoracoabdominal approach may be used (212, 213). The transhiatal approach (214) (Figure 
7) includes laparotomy, mediastinal dissection through the diaphragmatic hiatus and cervicotomy 
for a neck anastomosis. The recommended extent of resection margins is at least 5 cm in the distal 
stomach and at least 3 cm in the proximal esophagus and frozen section sampling of the margins 
during the operation is mandatory (173, 215-217). The extent of lymphadenectomy is more 
controversial. Two-field lymphadenectomy, i.e. dissection of nodes in the abdomen and chest from 
laparotomy and right thoracotomy, is the most common method (218). Three-field dissection 
includes cervical nodes along recurrent laryngeal nerves in addition to two-field dissection and it is 
most common in Japan, where squamous histology predominates (219, 220). In a randomized study 
between two- and three-field lymphadenectomy by Nishihara et al. (219), three-field dissection was 
associated with increased rates of complications without significant survival benefits. The 
thranshiatal approach has been criticized because all the thoracic nodes are not accessed. Meta-
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analyzes (221) and also randomized studies (170, 171, 222, 223) have compared the results of 
different operation methods for esophageal cancer and no significant differences have been shown 
in overall survival for the various operation methods. Most commonly, reconstruction is done with 
the gastric tube pull-up and anastomosis is carried out at the carinal level or neck (218). Neck 
anastomosis is necessary in the transhiatal operation, but in the transthoracic approach either neck- 
or intrathoracal anastomosis can be done, with the outcomes being similar in both and the 
additional resection of the esophagus that must be done for cervical anastomosis does not seem to 
affect the outcome (224, 225). Colonic interposition is a secondary option used if the stomach 
cannot be used (226). 
Surgery for esophageal cancer is complex and the risks for complications and mortality are high. For 
example, in American units with less than 10 esophagectomies per year, mortality can be as high as 
20% and this decreases to less than 10% in units with more than 20 operations per year (32). In the 
1950s, mortality was close to 30% and nowadays experienced units reach 2-5% mortality rates (227, 
228). The main complications after esophagectomy are anastomotic leak with mediastinitis, 
respiratory failure and cardiovascular complications (229, 230). In a prospective cohort of the United 
States Department of Veterans Affairs database, 1777 patients undergoing esophagectomy had a 
perioperative mortality of 10% and overall morbidity of 50% (31). The most frequent complications 
were pneumonia (21%) and respiratory failure (16%). Transhiatal (TH) and transthoracic (TTE) 
operations were randomized in a study by Hulscher et al. (171). There was a nonsignificant trend 
for improved overall survival in the transthoracic group and less complications in the TH group with 
shorter median hospital (TH 15 days (4-63) vs TTE 19 days (7-154), p<0.001) and intensive care unit 
(ICU) stays (transhiatal 2 days (0-38) vs. transthoracic 6 days (0-79), p<0.001). In a later subgroup 
analysis of the same material (170), patients in the TTE group without involvement of the cardia, 
had significantly better long-term survival than corresponding patients in the TH group. The rate of 
respiratory complications was as high as 57% in the TTE group as compared to 27% in the TH group 
(p=0.001). Mortality (2% TH vs. 4% TTE) and anastomotic leaks (14% TH vs. 16% TTE) rates did not 
differ significantly.  
Minimally invasive esophagectomy (MIE) is a novel method introduced by Cushieri 1992 (231) and 
further developed and popularized in experienced esophageal centers (232). Its aim is to reduce 
complications with the thoraco- and laparoscopic approach, while maintaining the radical nature of 
transthoracic Ivor-Lewis /Mckeown esophagectomy (OE). MIE encompasses a variety of methods 
ranging from total thoraco-laparoscopic resection and combinations of thoratomy/laparoscopy, 
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laparotomy/thoracoscopy, laparoscopic transhiatal to robotic assisted resections (233). Luketich et 
al. (232) have published a retrospective series of 1000 consecutive totally thoraco-laparoscopic 
MIE’s, with a median stay in ICU of 2 days (1–3), hospital stay of 8 days (6–14), and 30-day operative 
mortality of 1.7%. Meta-Analyses of retrospective studies, mostly single center cohorts, 
demonstrate similar outcome as compared to OE with two-field lymph node dissection. Generally, 
in MIE patients, hospital stay is shorter, blood loss is less and there are fewer pulmonary 
complications (43-45, 234). Dantoc et al. (235) analyzed oncologic outcomes in 16 comparative 
studies (MIE vs. OE), and the rate of R0 resections, the amount of retrieved lymph nodes and short-
term survival seem to be equivalent. Biere et al. (46) have published the so far only randomized 
study comparing MIE to OE, with primary end point respiratory complications. The hospital length 
of stay was shorter in patients who underwent MIE (11 vs. 14 days), and there were fewer 
pulmonary infections in the MIE group (9% within 2 weeks of MIE vs. 29% after OE). The rates of 
leaks (7% OE vs. 12% MIE) and in-hospital mortality (2% for OE and 3% for MIE) did not differ. 
Luketich et al. (40) published the results of a prospective non-randomized multicenter study 
evaluating the feasibility of MIE in a multicenter setting. The protocol operation was completed in 
95 of 104 patients with 2.1% perioperative mortality, an 11.4% rate of leak, a 5% rate of pneumonia, 
a 5.7% rate of ARDS level respiratory failure and 61% total rate of complications. Median ICU stay 
was 2 days and median total hospital stay was 9 days. At the three-year follow up, 58.4% of patients 
were alive. Overall, the feasibility of MIE in high-volume experienced centers has been successfully 
demonstrated and short-term oncologic results seem comparable to open esophagectomy.  
The selection of optimal treatment requires an exhaustive workup to determine the correct stage 
and subsequent treatment. The patient’s ability to tolerate both neoadjuvant treatment and radical 
esophagectomy should be evaluated. The experience of the surgical team and also the institution’s 
tradition in esophageal surgery are important determinants of optimal outcome regardless of the 
approach used. For example, MIE requires that surgical teams have extensive experience in 
minimally invasive surgery and preferably training in a high volume center before starting a 
program. 
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Figure 6. Transthoracic approach to esophagectomy. Reproduced with permission from 
Kitajima et al. NEJM 2002 (236), copyright Massachusetts Medical Society. 
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Figure 7. Transhiatal approach to esophagectomy. Reproduced with permission from 
Kitajima et al. NEJM 2002 (236), copyright Massachusetts Medical Society. 
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6 AIMS OF THE PRESENT STUDY 
 
I  To evaluate the presence of oxidative stress in proximal gastric mucosa, in patients 
with Barrett’s esophagus and/or esophageal adenocarcinoma. 
II To evaluate the long term prognosis and causes of death of patients with early stage 
esophageal adenocarcinoma. 
III To evaluate the accuracy of FDG-PET-CT in predicting survival and response to 
neoadjuvant chemotherapy in patients with locally advanced esophageal 
adenocarcinoma. 
IV To compare surgical and oncological outcomes of minimally invasive and open 
esophagectomy in the treatment of locally advanced esophageal adenocarcinoma. 
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7 PATIENTS AND METHODS 
 
7.1 Patients  
Study I included 57 patients treated at Helsinki University Hospital. Nine samples were from patients 
with only BE, nine from patients with esophageal AC and 24 had both BE and esophageal AC. The 
control group consisted of 15 patients with healthy esophagi and stomachs as assessed by 
endoscopic examination. Study patients records were evaluated to obtain their HPI histories. 
Study II included 85 patients operated on for superficial esophageal AC during 1984-2011, at the 
Department of General Thoracic and Esophageal Surgery at Helsinki University Hospital in Finland, 
at the Department of General and Abdominal Surgery at the University Medical Center, Mainz, 
Germany, and at the Division of Gastroenterologic Surgery at Tampere University Hospital in 
Finland. Pathology reports and medical records of the patients were evaluated and pathology 
samples re-evaluated. Cause-of-death data were acquired from the Finnish and German national 
death registries. 
Study III included 66 patients operated on for locally advanced esophageal AC and treated 
preoperatively with neoadjuvant chemotherapy, at the department of General Thoracic and 
Esophageal Surgery at Helsinki University Central Hospital between 2005-2011. The patients were 
consecutively staged with FDG-PET-CT before and after neoadjuvant chemotherapy in addition to 
normal staging procedures. 
Study IV included 153 patients undergoing surgery for locally advanced esophageal adenocarcinoma 
between 2003 and 2013. Of these, 74 were minimally invasive esophagectomies and 79 open 
transthoracic esophagectomies. The types of data assessed were oncologic, intraoperative, and 
postoperative.  
 
7.2 Methods 
7.2.1. Tissue sample collection 
In study I, samples were acquired during endoscopy from BE follow-up patients and pre-treatment 
endoscopy of esophageal AC patients, or from a resected specimen during the operation (11 of 
esophageal AC samples). During endoscopy the most obvious area of pathology was sampled with 
biopsy forceps and if present, both tumor and metaplastic mucosa were sampled. Proximal gastric 
mucosal samples were taken 5 cm below the top of proximal gastric folds to gain gastric mucosal 
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samples of the cardiac region (56), instead of junctional or esophageal tissue. In the control patients, 
squamous epithelium samples were taken 5 cm above the gastroesophageal junction and proximal 
gastric mucosal samples were taken as in study group. All the samples were immediately frozen and 
stored at -70 Celsius and were later on sent for analysis.  
 
7.2.2. Biochemical analysis of collected samples 
Biochemical analyzes were carried out with commercial kits at Turku University Institution of 
Biochemical Sciences. 8-Isoprostanes were determined by STAT-8-Isoprostane EIA Kit (Cayman 
Chemical, Ann Arbor, MI, USA). Glutathione reduced form (GSH) and glutathione oxidized form 
(GSSG) were measured by Glutathione Assay Kit by Cayman Chemical. 8-OH-deoxyguanosine was 
measured by the OxiSelectTM Oxidative DNA Damage ELISA Kit (8-OHdG) (Cell Biolabs, Inc., San 
Diego, CA, USA). 
 
7.2.3. Histopathologic analysis 
In studies II & III, pathology slides from the original operations were acquired and re-analyzed by an 
experienced gastropathologist. In study II, the depth of infiltration of the tumor was re-evaluated 
and re-classified by dividing both the mucosa and submucosa into three layers (m1-3 & sm1-3) (186). 
In study III, resected specimen slides were evaluated for the presence of viable cancer cells and the 
response was graded according to the histomorphologic regression grading system of Schneider et 
al. (179). Tumor bed specimens were classified as grades I to IV, grade I meaning more than 50% 
living tumor cells in the tumor bed, grade II, 10% to 50% living tumor cells, grade III, less than 10% 
and grade IV, no living tumor cells. Grades III to IV were classified as histopathologic responders and 
grade I to II as the non-responder group.  
 
7.2.4 Staging 
Staging of patients in studies II-IV included OEGD, an iv-contrasted spiral CT-scan of the thorax, 
abdomen, and pelvis (3–5 mm slice thickness), EUS, and FDG-PET-CT. PET was done before and after 
induction therapy.  
 
7.2.5 Positron emission tomography imaging of neoadjuvant therapy response 
Patients in study III were scanned with a dedicated whole-body scanner at Helsinki University 
Central Hospital, and three patients at the Turku PET Centre. We determined their heights and 
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weights and measured the serum glucose levels of diabetic patients. The dose of FDG was 5 MBq/kg 
body weight and the scan started one hour after the FDG injection. Standardized uptake values 
(SUV) were determined with a small fixed-dimension region of interest (ROI), 8 mm in diameter; and 
the value was determined using the highest activity inside this area. SUV values were calculated 
accordingly after correction for radioactive decay. The SUV of the primary tumor was determined 
at the baseline and after therapy. A second PET scan was done within one month after the last cycle 
of chemotherapy. The maximal SUV of the pretreatment scan was labeled SUV1, and the post-
treatment scan SUV2. The change percentage (SUVΔ%) was expressed as [(SUV1- SUV2)/SUV1]x100.  
 
7.2.6 Neoadjuvant therapy 
Patients in studies III and IV were preoperatively treated with neoadjuvant chemotherapy, 
according to the protocol published by Cunningham et al. (195). In study III, 53 patients received 
epirubicin-oxaliplatin-cabecitabine (EOX), four received epirubicin-cisplatin-fluorouracil, and nine, a 
docetaxel-cisplatin-fluorouracil combination. In study IV 78% of the patients in the open 
esophagectomy group received neoadjuvant therapy, and of these 62% had chemotherapy and 15% 
radiochemotherapy. In the minimally invasive group, 82% of patients had neoadjuvant therapy and 
of these, 74% was chemotherapy and 4% chemoradiotherapy. In study IV, since 2007, eligible 
patients have been treated with epirubicin-oxaliplatin-capecitabine neoadjuvant chemotherapy. 
Prior to this, selected patients received various types of chemotherapy or chemoradiotherapy. 
Chemoradiotherapy consisted of platin- and 5-fluorouracil-based therapy over 5–6 weeks, followed 
by a 45-gy total dose of radiation to the tumor and regional nodes. 
  
7.2.7 Surgical methods  
In our institution, the routine approach to esophageal AC has been two-field lymphadenectomy 
done from laparotomy and right posterolateral thoracotomy or laparoscopy and right thoracoscopy. 
Earlier, in selected cases, transhiatal resection was carried out. Some of patients in study II were 
operated on in Mainz, Germany, and most resections were transhiatal.  
Two-field resection for AC of the distal esophagus and/or gastric cardia, included resection of the 
proximal stomach with a 10 cm margin to the tumor and the distal esophagus at the level of tracheal 
carina. The proximal resection margin is checked to be at least 5 cm if possible, and confirmed with 
a frozen section. Adjacent tissues and lymph nodes are removed en bloc with the specimen, from 
the superior border of pancreas to the carina. The lymph nodes are resected along the splenic 
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artery, along the celiac artery, nodes associated with the left gastric artery and nodes in the 
parahiatal and -esophageal areas. The rim of the hiatal muscle, both pulmonary ligaments, 
mediastinal pleura and thoracic duct are included in the specimen. In minimally invasive 
esophagectomy, exactly the same resection is done, except that the thoracic duct is usually spared. 
The thoracic part of the resection is done in the left lateral decubitus position with one-lung 
ventilation in both the minimally invasive and open approaches. Reconstruction is done with a 
gastric tube created with a stapling device. Esophagogastric anastomosis was done mainly 
intrathoracally in both groups, stapled anastomosis with a DSTTM EEATM circular 25-28 mm stapler 
(Covidien, Mansfield, MA), and hand-sewn anastomosis in two layers with absorbable 4-0 sutures 
(PDS). In the transhiatal technique, the thoracic cavity was not entered and after abdominal 
dissection, the esophagus was bluntly removed through a diaphragmatic hiatus and a hand-sewn 
anastomosis was constructed from a left-sided neck incision. 
In study II, there were 5 patients whose tumors were resected endoscopically due to comorbid 
conditions precluding surgery. Mucosal resection was carried out by lifting the mucosa with a 
suction cap and rubber band ligature, the lifted mucosa was resected with a diathermy snare (184). 
Endoscopic procedures were carried out under deep sedation supervised by an anesthesiologist. 
 
7.2.8 Statistical methods 
The rarity of esophageal cancer limits possibilities for randomization and prospective trials. 
Therefore the data used in these studies is retrospective. In all studies, values were expressed as 
medians with ranges, or means with standard deviations. All p-values were based on two-tailed tests 
and significance was set at <0.05. In study I, comparisons of medians and distributions across groups 
were compared with the Mann Whitney U-test. In study II, III and IV, comparisons of categorical 
variables were done with the chi-square test, and for continuous variables the Kruskal–Wallis, Mann 
Whitney U, or independent samples median-test were used. Survival rates were estimated 
according to Kaplan–Meier. Statistical comparisons of survival between groups of patients were 
performed with a log-rank test, and multivariate survival analysis by the Cox proportional hazards 
model. Overall, disease-specific, and recurrence-free survival rates were calculated from the date 
of operation and in study IV, from the start of neoadjuvant treatment. The endpoint was defined as 
death from any cause for overall survival, as cancer-related death for disease-specific survival, and 
local or distal recurrence for recurrence-free survival. In study IV, the diagnostic accuracy of FDG-
PET-CT was calculated by the receiver operating characteristics (ROC) test.  
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8 RESULTS 
 
8.1 Study I  
The results are presented in Figure 8. A marker of lipid peroxidation, 8-IP, was present in proximal 
stomach of patients with esophageal AC and / or BE (study group), and its content was significantly 
higher than in proximal gastric folds of control patients (p=0.039). Similarly, the amount of a marker 
for oxidative DNA damage, 8-OHdG, was significantly higher in the proximal gastric folds of the study 
than the control group (p=0.008). An antioxidant buffer in the form of GSH, was present in a 
significantly smaller concentration in the proximal stomachs of the study - than the control group 
(p=0.031). The concentration of GSSG in the proximal stomach of the study and control groups did 
not differ with any statistical significance. The amounts of 8-IP and 8-OHdG were significantly higher 
and GSH significantly lower when comparing the study group samples of BE mucosa and tumor, to 
the control patients- samples above the ge-junction. HPI was present in 8% of the study group and 
in none of the control patients. 
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Figure 8. Comparisons of 8-isoprostane (8-IP), 8-OH-deoxyguanosine (8-OHdG), oxidized glutathione 
(GSH) and the reduced form (GSSG) levels between the study and control groups. Mann Whitney U 
test. 
 
 
  
41 
8.2 Study II 
In the histopathological reclassification, the disease was intramucosal in 35 (44%), and submucosal 
in 44 (56%) of the patients. The rate of lymph node metastases (LNM) was 3% in intramucosal 
tumors, 9% in submucosal SM1 -tumors, 20% in the SM2-3 layer. Of 35 T1a patients, 13 (37%) had 
an en bloc transthoracic esophagectomy, 15 (43%) transhiatal esophagectomy, 4 (11%) vagal 
sparing esophagectomy and 3 (9%) EMR. Of the 44 T1b patients, 20 (45%) had an en bloc 
transthoracic esophagectomy, 21 (47%) had transhiatal, 2 (5%) patients had EMR and one (2%) had 
a vagal sparing esophagectomy. 
The median follow-up was 5 years (range 0–26 years). Overall survival probability was 67% at 5 years 
and 50% at 10 years (Figure 9a). The disease-specific survival probability was 82% at 5 years and 
78% at 10 years (Figure 9b). At 5 years of follow-up, 80% were recurrence free with no new 
recurrences after 5 years of follow-up.  
The in-hospital mortality from postoperative complications was 4 patients (5%). Mortality due to 
recurrent disease was 15 (18%) patients, 5 (6%) another primary malignancy, and 11 (13%) of non-
cancer-related causes. The cause of death for 2 (2%) is unknown.  
The overall risk for recurrence of SEAC was 18%. Recurrence risk was 9% for intramucosal and 27% 
for submucosal SEAC. In univariate and multivariate analyses, regional lymph node metastases were 
significantly associated with poor survival for overall, disease-specific and recurrence free survival. 
Disease-specific and recurrence-free survivals were also significantly affected by depth of infiltration 
in both uni- and multivariate analyses.  
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Figure 9. Survival of patients with superficial esophageal adenocarcinoma (n=85) calculated 
according to Kaplan-Meier. 
 
8.3 Study III 
The change of maximal SUV (SUVΔ%) between sequential PET scans before and after neoadjuvant 
therapy was significantly (p<0.0001) more prominent in histopathologic responders than in non-
responders. A decrease of 67% in maximal SUV was the optimal cut-off value differentiating 
between histopathologic responders and non-responders, giving a sensitivity of 79% and specificity 
of 75%. If a lower cut-off of 35% was used, a sensitivity of 100% and specificity of 33% were reached. 
Total loss of uptake in second scan, did not equal complete histopathologic response. 
Median follow-up was 16 months (range 4–72). Overall survival was 59% and disease-free survival 
50% at three years after the start of neoadjuvant therapy. For the univariate Cox regression 
proportional hazards regression test (Figure 10), the SUVΔ% of 67% and histopathologic response 
were both associated with improved recurrence free time When SUVΔ% was used as a continuous 
variable, it is an independent predictor of both overall and disease-free survival in the Cox 
multivariate model. In 8 patients there was no regression in maximal SUV of the primary tumor, or 
the second scan showed increased activity. In these patients AC recurrence was detected within one 
year after beginning the treatment. 
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Figure 10. Cox regression proportional hazards univariate analysis of the effect of the 
histopathologic response (HPR) and percentage (>67%) change of maximal standardized uptake 
value of the primary tumor (SUVΔ%) on disease free survival (DFS). 
 
8.4 Study IV  
Comparing surgical outcomes between OE and MIE, the overall complication rate was also similar 
(60% for OE and 50% for MIE, p=0.181). The rates of the most important complications - anastomotic 
leak, conduit necrosis, pneumonia, respiratory failure and re-operations did not differ with any 
significance. Blood loss during surgery was significantly less for MIE (OE 800 (110–4,000) ml vs. MIE 
300 (50–3,000) ml, p<0.0001). ICU stay did not differ, but the median for overall length of hospital 
stay was less for MIE (14 (9–63) days with OE and 13 (6–87) days with MIE, p=0.040).  
The median for follow-up after surgery was 28 (0–116) months. In the OE group, 61% of the patients 
were followed for under, and 39% for over three years, with 31% for over 5 years. In the MIE group, 
75% of patients were followed for under, and 24% for over three years. Only 4% have reached the 
5-year follow up in the MIE group. There were no significant differences in overall 3- (OE 49% vs. 
MIE 64%) or 5-year (OE 41% vs. MIE 56%) survival rates (p=0.321). Recurrence-free survival for 3 
years was 53% for OE and 57% for MIE (p=0.911). The rate of R1 resection in the OE group was 2 
versus 1% in the MIE group (p=0.522). The median for harvested nodes was less in the MIE group, 
20 (4–49) than in the OE group, 22 (8–58), (p=0.021). Overall, male gender and pathological stage 
over 2B remained significant for overall survival in the multivariate COX model, and therefore these 
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variables are independent predictors. The multivariate model showed that type of operation did not 
affect survival.  
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9 DISCUSSION 
 
9.1 Pathogenesis 
In study I, we were able to show OS, oxidative DNA damage and antioxidative capacity reduction in 
the proximal stomachs, in the BE mucosa and the AC tissue of the study group as compared to the 
healthy controls. The most common cause of cardiac and proximal stomach mucosa inflammation 
is known to be HPI, but its presence is known to reduce the risk of esophageal AC (29, 49, 117, 118, 
237). Similarly, in our study, only 8% of study patients had a previous history of HPI. A group of 
patients with carditis, which is not associated with HPI, but is strongly correlated with GERD and 
erosive esophagitis, is known to exist (28). In our study group, patients also had BE and esophageal 
AC, which are known to be GERD related. Therefore, it may be that inflammation and OS in the 
cardiac region are also connected to GERD related esophagitis. Another cause of gastric 
inflammation is duodenogastric reflux, which is known to cause gastritis in patients with partial 
gastrectomy (238). Overall it is likely that gastroduodenal contents cause injury not only to the 
esophageal mucosa, but they may also directly injure the proximal stomachs mucosa causing 
chronic inflammation and OS. 
OS is a result of imbalance of oxygen metabolism as a result of chronic inflammation and it has been 
suggested to be associated with pathogenesis of esophageal AC (23-26) and other gastrointestinal 
tract malignancies (87-89). Our results further strengthen the role of gastroduodenal content 
related inflammation and oxidative damage behind pathogenetic processes ultimately leading to 
esophageal AC. This also may further clarify the pathogenesis of AC within the cardiac region.  
 
9.2 Prognosis  
In study II, the most frequent cause of death was recurrent cancer within 5 years of follow-up and 
after that, causes of death related to aging dominated. No new recurrence was detected after five 
years of follow-up, which is in line with the literature (239-241) Overall survival was 67% at 5 years 
and 50% at 10 years, which is comparable to previously published series (160, 161, 163, 165, 166, 
242, 243). The presence of regional lymph node metastases was independently associated with 
overall, disease-specific and recurrence-free survival in the multivariate Cox model. In the same 
analysis, the depth of tumor infiltration was independently associated with recurrence and disease 
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specific survival. These are also in line with what has been previously published for lymph node 
metastases (173, 175-177) and depth of tumor infiltration (177, 178). 
In study III, the overall survival of patients with locally advanced disease and the multimodality 
approach, was 57% at three years after surgery and 50% of the patients were disease free at three 
years. In study IV, three-year survival was 49% for the OE and 64% for MIE groups and at five years, 
survival was 41% for the open- and 56% for the minimally invasive approach. The survival of patients 
with locally advanced AC of the esophagus is reported to be 15-35% at 5 years after surgical therapy 
(9, 172) and the best series report survival to be up to 50% after multimodality therapy (39, 168-
171), which compares well with our results. In study III, metabolic response (decrease of metabolic 
activity between PET scans before and after neoadjuvat chemotherapy) was the strongest 
prognosticator of recurrence and overall survival. A histopathologic response and a pathologic stage 
<2B (48) predicted recurrence in the univariate model. In the literature, histopathologic response 
and lymph node metastases are the strongest predictors of survival after multimodality treatment 
(37, 179, 180). In our study, the small number of patients may limit the accuracy of statistics and 
most studies using PET in response evaluation have been done after chemoradiotherapy, thus they 
are not directly comparable due to post radiation inflammation disturbing the second PET scan (146, 
147, 151-153). However, after neoadjuvant chemotherapy, the results are similar to ours regarding 
prediction of survival after treatment (38, 41, 149, 150). 
 
9.3 Staging 
Neoadjuvant therapy has improved the prognosis of patients with locally advanced esophageal AC 
(35, 36). Patients with complete eradication of malignant cells from the surgical specimen after 
neoadjuvant chemo- or chemoradiotherapy may have excellent 5-year survival rates (37, 179, 180). 
In study III, we evaluated the accuracy of FDG-PET-CT in the prediction of histopathologic regression 
of esophageal AC. A decrease of 67% of metabolic activity between PET scans before and after 
neoadjuvant chemotherapy predicted histopathologic regression with a sensitivity of 79% and 
specificity of 75%. With a lower cut-off of 35%, a sensitivity of 100% and specificity of 33% was 
reached, this result is similar to those previously published (41, 149, 150, 244). Overall, accuracy of 
FDG-PET-CT in predicting response and survival seems insufficient to justify withdrawal from surgery 
based on degree of treatment response only. If primary tumor metabolic activity did not decrease, 
or increased after neoadjuvant therapy, the prognosis was poor – disease recurrence was detected 
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within one year of beginning treatment. This information could be useful in decision-making, 
especially in patients with borderline general condition for radical esophagectomy. 
 
9.4 Treatment 
9.4.1 Stage 0-Ia 
Surgical treatment of esophageal cancer is associated with substantial morbidity and also mortality, 
especially in lower volume centers (31, 32). In superficial esophageal AC, treatment has shifted from 
radical resection to endoscopic ablation. Recent guidelines suggest endoscopic ablation for patients 
with HGD and intramucosal (pT1a), when lesion size is <20 mm, the lesion is well or moderately 
differentiated and no lymphovascular infiltration is present (33, 245, 246). In study II we evaluated 
prognosis and risk for recurrence in early esophageal AC (pT1a and pT1b) after surgical resection. 
Overall survival was mainly affected by causes related to aging in the long-term (>5 year) follow-up 
and 80% patients were recurrence free at 5 years. The risk for recurrence in patients with T1a AC 
was 9%, which was higher than previously published 0-3% (190, 239, 240, 247). This could be 
explained by staging bias, as lymph node metastases may have been missed. For example, in 
transhiatal esophagectomy, no formal lymph node dissection is done intrathoracally. Also, the 
staging for early esophageal AC requires the skills of specialist pathologists because differentiating 
between T1a and T1b may be difficult. In a meta-analysis, long-term survival in the treatment of 
early esophageal cancer and high-grade dysplasia does not seem to differ (167). Also, RFA in 
addition to EMR afford us simple and reproducible means for the eradication of associated BE 
mucosa (242). Therefore, especially in patients with HGD, the aim should be for endoscopic 
eradication to avoid substantial morbidity and risk for mortality associated with esophagectomy. 
The individualized approach should be emphasized in intramucosal cancer. If significant risk factors 
for recurrence are present the aim should be for surgery in eligible patients and in patients with 
high risk for surgery, the aim should be for endoscopic ablation. 
 
9.4.2. Stage Ib-III 
In patients with submucosal AC, the overall risk of lymph node metastases was 20% in sm2-3 and 
overall risk for recurrence 27%, results in accordance with previously published results (160, 173, 
178, 187, 188, 242). With higher risks for metastasis and recurrence, radical surgery is 
recommended generally (9, 33, 248). A German group (189) reported favorable long-term survival 
after mucosal resection of submucosal esophageal AC, in a group with sm1 level infiltration, well to 
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moderate differentiation and no lymphovascular infiltration. If low risk patients can be reliably 
identified by pathologists, endoscopic ablation may be a viable alternative for patients, even for 
those in the superficial pT1b category, at high risk of not undergoing successful surgery. 
MIE has been developed to decrease the rate of pulmonary complications after traditional OE (231, 
232). In study IV, we compared the perioperative and oncologic results of OE and MIE following 
esophageal resection, for locally advanced esophageal AC after neoadjuvant chemotherapy. One-
month mortality rates and also three-month mortality rates were both low, as compared to series 
from high volume centers (31, 42, 46, 170) and they did not differ from each other with any 
significance. The anastomotic leak rates and rates of respiratory complications did not differ and 
the overall rates of complications were similar. Statistical difference was seen in intraoperative 
bleeding and total hospital stay in favor of the minimally invasive approach. Less pulmonary 
complications, less operative bleeding, a shorter hospital time for MIE, and similar rates of 
anastomotic leaks between the OE and MIE approaches are reported in meta-analyses (43-45, 234) 
and a recent randomized trial (46). These results are in line with ours. In our study, the rate of R0 
resections was the same and short-term (three-year) survival did not differ with any significance. 
The number of retrieved lymph nodes was higher for open esophagectomy, but for MIE, the median 
of retrieved nodes was 20, a result similar to reports from meta-analyses (234, 235). The incidence 
of late complications did not differ between the OE and MIE approaches. 
Overall, MIE appears to be comparable to traditional OE when comparing postoperative results and 
it achieves the same oncologic radicality with comparable short-term survival rates. Our series also 
includes the learning curve for a new, very demanding technique, and our results should be 
expected to be even better in future. Surgery and treatment for esophageal cancer overall, is 
complex and requires an experienced multidisciplinary team. Treatment options range from 
endoscopic therapies to different surgical resections. The surgical team should be able to handle all 
methods and tailor treatments to match their patients’ reserves. 
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10 CONCLUSIONS 
 
1. In proximal gastric mucosa of patients with Barrett’s esophagus and esophageal 
adenocarcinoma, elevated oxidative stress, increased oxidative DNA damage and depleted 
antioxidative buffer concentrations can be measured. 
 
2. In early esophageal adenocarcinoma, half of the patients were alive 10 year after the 
operation. Cancer recurrence was the most common cause of death during the 5-year 
follow-up, and after that, diseases related to aging. 
 
3. The accuracy of FDG-PET-CT was not good enough to guide clinical decision-making, based 
on this modality alone. An over 67% decrease in the metabolic activity of the primary tumor 
was associated with a 4-fold decrease in the of risk death due to esophageal 
adenocarcinoma. 
 
4. As compared to open esophagectomy, minimally invasive esophagectomy shortens overall 
stay in hospital and is associated with less blood loss during the operation. The rates of 
complications or re-operations do not differ with any significance. The oncologic results are 
also comparable, as the rates of complete resection and 3-year survival are similar. 
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11 YHTEENVETO (FINNISH SUMMARY) 
 
Ruokatorven ja mahansuun adenokarsinooma on huonoennusteinen tauti, jonka ilmaantuvuus 
länsimaissa on ollut nousussa viime vuosikymmeninä. Sen patogeneesi liittyy gastroduodenaalisen 
refluksin aiheuttamaan krooniseen tulehdukseen ja oksidatiiviseen stressiin ruokatorven 
limakalvolla. Parantuminen on mahdollista potilailla, joille tehdään onnistunut radikaali leikkaus ja 
joiden syövän aste on varhainen. Paikallisesti edenneissä tapauksissa paraneminen on mahdollista 
osalla potilaista, joiden leikkausta edeltää onnistunut onkologinen esihoito. Ruokatorvikirurgiaan 
liittyy paljon komplikaatioita ja merkittävä leikkauskuolleisuuden riski. Siksi on keskeistä löytää 
menetelmiä, jotka auttava löytämään leikkauksesta hyötyvät potilaat sekä selvittää myös 
vähemmän invasiivisten menetelmien tulokset.  
Tämän tutkimuksen tavoitteena oli 1) selvittää oksidatiivisen stressin merkitystä mahalaukun 
alkuosassa Barrett’n ruokatorven ja ruokatorven adenokarsinooman synnyssä, 2) arvioida 
varhaisvaiheen ruokatorven adenokarsinooman pitkäaikaisennusteta ja potilaiden kuolinsyitä, 3) 
arvioida kuinka 18F-fluorodeoksi-D-glukoosi-positroniemissiotomografia liitettynä tietokone-
tomografiaan (FDG-PET-CT) ennustaa kirurgiaa edeltävän kemoterapian vastetta ruokatorven 
adenokarsinooman hoidossa ja 4) verrata mini-invasiivisen radikaalileikkauksen tuloksia avoimeen 
ruokatorven syövän leikkaukseen. 
Ensimmäisessä osatyössä potilasaineisto koostui 43 tutkimus- ja 15 kontrollipotilaasta, joiden 
ruokatorven ja mahansuun limakalvoilta mittaukset tehtiin. Oksidatiivista stressiä määritettiin 
mittaamalla 8-isoprostaanipitoisuus. Antioksidanttikapasiteettia varten mitattiin glutationin 
hapettuneen ja pelkistyneen muodon pitoisuudet ja vaurioituneen DNA:n tunnistamiseksi mitattiin 
8-OH-deoksiglukoosipitoisuus. Toisessa osatyössä varhaisvaiheen ruokatorven adenokarsinooman 
pitkäaikaisennusteen ja kuolinsyiden määrittämiseksi tutkittiin potilasarkiston ja kuolinsyyrekisterin 
tiedot 85:lta potilaalta joilta oli kirurgisesti hoidettu limakalvoon tai sen alaiseen kerrokseen 
rajoittuva tauti. Kolmannessa osatyössä arvioitiin kirurgiaa edeltävän kemoterapiana annetun 
esihoidon tehoa tekemällä FDG-PET-CT kuvaus ennen ja jälkeen kemoterapian 66 potilaalle joille 
sen jälkeen tehtiin radikaali leikkaus. Tutkimuksessa arvioitiin kasvaimen aineenvaihdunnan 
aktiivisuuden muutoksen yhteyttä tuumorikudoksen katoon sekä potilaan ennusteeseen. Neljäs 
osatyö koostui leikkaustulosten vertailusta mini-invasiivisesti ja avoimesti tehtyjen leikkausten 
välillä. Vertailussa oli 75 mini-invasiivisesti ja 79 avoimesti leikattua potilasta, jotka sairastivat 
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paikallisesti levinnyttä ruokatorven adenokarsinoomaa. Tutkimuksessa verrattiin leikkauksen 
jälkeistä kuolleisuutta, komplikaatioita, leikkauksen onkologista radikaliteettia sekä ennustetta. 
Tutkimusten tulokset olivat seuraavat: 1) Mahalaukun alkuosan 8-isoprostaani sekä 8-OHdG 
pitoisuudet olivat korkeammalla tutkimus- kuin kontrolliryhmässä, ja ero oli tilastollisesti 
merkitsevä. Antioksidattikapasiteetti (glutationipitoisuus) oli merkitsevästi matalampi tutkimus-, 
kuin kontrolliryhmässä. 2) Ruokatorven varhaisvaiheen adenokarsinoomaa sairastavien potilaiden 
alle viiden vuoden kuolleisuus johtui taudin uusimisesta, kun taas pitkäaikaisennuste riippui 
ikääntymiseen liittyvistä kuolinsyistä. Viiden vuoden seurannan jälkeen 80 % potilaista oli 
tautivapaita, eikä uusia residiivejä tullut tämän jälkeen. 3) Paikallisesti edenneen ruokatorvisyövän 
täyttä häviämistä leikkauspreparaatista ennusti parhaiten 67 % lasku tuumorin FDG-PET-CT 
kuvauksen osoittamassa aktiivisuudessa esihoidon jälkeen(sensitiivisyys 79 % ja spesifisyys 75 %). 
PET-aktiivisuuden lasku jatkuvana muuttujana, oli monimuuttujamallissa yhteydessä potilaiden 
kokonaisennusteeseen itsenäisenäkin ennustetekijänä. 4) Mini-invasiivinen ja avoin tekniikka olivat 
yhteneväisiä tuloksiltaan kolmen kuukauden kuolleisuuden, komplikaatioiden kokonaismäärän ja 
kolmen vuoden elossaololukujen suhteen. Mini-invasiivisen tekniikan käyttöön liittyi vähäisempi 
verenvuoto leikkauksen aikana sekä lyhyempi sairaalahoitoaika. Tutkimustemme johtopäätökset 
olivat seuraavat: 1) Barrett- ja ruokatorven adenokarsinoomapotilaiden mahalaukun alkuosan 
oksidatiivinen stressi on lisääntynyt, koska 8-isoprostaanitaso on kohonnut ja 
antioksidanttikapasiteetti vähentynyt verrattuna terveisiin verrokkeihin. Myös hapettumisen 
vaurioittamaa DNA:ta voidaan todeta merkitsevästi enemmän kuin verrokeilla. Näin ollen 
mahalaukun alkuosan oksidatiivisella stressillä voi olla osuutensa Barrettin ruokatorven ja 
ruokatorven adenokarsinooman kehittymisessä. 2) Ruokatorven adenokarsinooman varhaisasteen 
tautikohtainen ennuste oli hyvä, mutta taudin uusiminen oli silti yleisin kuolinsyy. Riski oli korkein 
potilailla, joilla oli paikallisten imusolmukkeiden metastaaseja ja tuumori kasvoi limakalvonalaiseen 
kerrokseen. Näinollen kirurgisen hoidon tulee edelleen olla ensisijainen menetelmä, varsinkin 
limakalvon alaiseen kerrokseen kasvavilla syövillä, ja endoskooppisia hoitomenetelmiä harkita 
valikoidusti. 3) FDG-PET-CT:n tarkkuus ei ollut riittävää ohjaamaan hoitopäätöksiä muutoin, kuin 
metastasoinnin ja tautiprogression poissulkemisen osalta. Kuitenkin PET-aktiivisuuden lasku oli 
yhteydessä potilaan parempaan ennusteeseen ja tämä tieto on hyödyksi pohdittaessa 
leikkauspäätöstä rajatapauksissa leikkauskelpoisuuden suhteen. 4) Mini-invasiivinen tekniikka 
osoittautui yhtä hyväksi kuin avotekniikka myös paikallisesti edenneen syövän hoidossa ja näyttää 
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lyhentävän hoitoaikaa. Se on kuitenkin teknisesti vaativampi ja edellyttää riittävää potilasmäärää ja 
kokemusta jotta etu avokirurgiaan nähden saavutetaan. 
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